UPDATE: Bristol-Myers Selects Drug Targets from Lexicon s LexVision | GenomeWeb

NEW YORK, Aug. 8 – Lexicon Genetics said on Wednesday that Bristol-Myers Squibb has chosen certain drug targets from its LexVision library of mouse gene-knockout data to move into drug development. 

The drug giant's decision is significant, Lexicon Chief Financial Officer Julia Gregory told GenomeWeb , because it is the first time a subscriber to the database has identified particularly promising drug targets. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: a global genetic interaction map for Saccharomyces cerevisiae, and progress made in genomics, precision medicine, and therapeutics.

The price of plane tickets can affect how scientists in different countries choose to collaborate with each other, NPR reports.

The Annals of Improbable Research has awarded the 2016 Ig Nobel Prizes.

Scientific American alleges that the FDA has been "arm-twisting journalists into relinquishing their reportorial independence."